Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $15.0 million.

  • Burning Rock Biotech's Current Deferred Revenue fell 524.68% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year decrease of 524.68%. This contributed to the annual value of $16.2 million for FY2024, which is 1215.05% down from last year.
  • Burning Rock Biotech's Current Deferred Revenue amounted to $15.0 million in Q3 2025, which was down 524.68% from $14.4 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Current Deferred Revenue ranged from a high of $133.5 million in Q4 2021 and a low of $13.9 million during Q1 2021
  • For the 5-year period, Burning Rock Biotech's Current Deferred Revenue averaged around $24.7 million, with its median value being $18.4 million (2023).
  • In the last 5 years, Burning Rock Biotech's Current Deferred Revenue soared by 107064.81% in 2021 and then tumbled by 8396.5% in 2022.
  • Burning Rock Biotech's Current Deferred Revenue (Quarter) stood at $133.5 million in 2021, then tumbled by 83.96% to $21.4 million in 2022, then decreased by 14.1% to $18.4 million in 2023, then dropped by 12.15% to $16.2 million in 2024, then dropped by 7.42% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $14.4 million for Q2 2025, and $16.2 million during Q1 2025.